Global Diabetic Retinopathy
Global Diabetic Retinopathy

Diabetic Retinopathy Comprehensive Study by Type (Laser surgery, Injection of corticosteroids, Anti-VEGF drugs, Vitrectomy), Application (Hospitals, Clinics and laboratories, Others), Retinopathy (Proliferative Diabetic Retinopathy, Non-Proliferative Diabetic Retinopathy (NPDR)), Treatment (Anti-VEGF Drug, Vitrectomy, Intraocular Steroid Implants, Laser Surgeries) Players and Region - Global Market Outlook to 2026

Diabetic Retinopathy Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Mar 2021 Edition 222 Pages 210 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Diabetic Retinopathy Market Scope
Diabetic Retinopathy is a diabetes complication that affects eyes, this condition damages the blood vessels of the light-sensitive tissue on retina. Diabetes mellitus, a devastating illness that has reached epidemic proportions, is causing an increase in severe retinal problems around the world. Published literatures suggest that the number of diabetic conditions are estimated to more than double by 2040. Retinal disorders are prevalent among patients with Type 1 or Type 2 diabetes. Emerging regions leading including Asian economies comprising of huge portion of diabetic population. All these factors account for market growth potential for Diabetic Retinopathy.

The Diabetic Retinopathy market study is segmented by Type (Laser surgery, Injection of corticosteroids, Anti-VEGF drugs and Vitrectomy), by Application (Hospitals, Clinics and laboratories and Others) and major geographies with country level break-up.

The Diabetic Retinopathy market is highly consolidated, companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Diabetic Retinopathy market throughout the predicted period.

Abbott Laboratories (United States), Alimera Science (United States), Allergan PLC (India), Ampio Pharmaceuticals (United States), Bayer AG (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Novartis AG (Switzerland), Pfizer (United States), Regeneron Pharmaceuticals Inc. (United States) and Bausch Health (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are NovaGo Theraputics (Switzerland) and Eyenuk (United States).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Diabetic Retinopathy market by Type, Application and Region.

On the basis of geography, the market of Diabetic Retinopathy has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Leaders and their expansionary development strategies
On 21st September, 2020 - Bausch Health Acquired Option to Purchase Ophthalmology Assets of Allegro Ophthalmics, the Agreement Includes Global Rights for Risuteganib/Luminate (Allegro’s Key Retinal Investigation Compound). This Addition is Intended to Enhance Bausch’s Retinal Treatment Portfolio. and On 16th November, 2020 – Pfizer Completed Spinoff of its UPJohn Business with Mylan (Leading Specialty Pharmaceuticals Company), this Intended Spin-off is Aimed to Expand Pfizer’s Prevention and Treatment Capabilities across Segments Including Eyecare.
On 5th August, 2020 - Eyenuk Announced FDA Clearance for its “EyeArt” an Autonomous Artificial Intelligence (AI) Based System Designed for Diabetic Retinopathy Screening. and On 3rd February, 2021 – NovaGo (Biotech Start-up) Started Clinical Trials For its New “Fully Human Antibody Therapy” to Treat Diabetic Retinopathy.
World Health Organization, Diabetic retinopathy screening: a short guide: The Guide Suggests Optimal Techniques and Procedures Regarding Retinopathic Treatments. and United States, Food and Drug Administration; Main Regulatory Authority Responsible for Inspection and Approval of Companies Providing Healthcare Solutions Across the US. Any New Entrant or Technology should Seek Approval from the USFDA.

Market Trend
  • Technical Progress in Medical Industry
  • Heavy Investments in Healthcare Research & Development

Market Drivers
  • Prevalence of Diabetic Conditions Among Adults
  • Increasing Screen Time

Opportunities
  • Emergence of Advance and Effective Techniques
  • Growth in Healthcare infrastructure Due to Pandemic

Restraints
  • Highly Priced Procedures
  • Complications Leading to Several Vision Problems

Challenges
  • Lack of Trained Professionals


Key Target Audience
Diabetic Retinopathy Surgical Equipment Manufactures, Hospitals and Clinics, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

Frequently asked questions:
1. Is it possible to have certain customization in the study?
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.

2. How big is the Diabetic Retinopathy Market?
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.

Report Objectives / Segmentation Covered
By Type
  • Laser surgery
  • Injection of corticosteroids
  • Anti-VEGF drugs
  • Vitrectomy
By Application
  • Hospitals
  • Clinics and laboratories
  • Others
By Retinopathy
  • Proliferative Diabetic Retinopathy
  • Non-Proliferative Diabetic Retinopathy (NPDR)

By Treatment
  • Anti-VEGF Drug
  • Vitrectomy
  • Intraocular Steroid Implants
  • Laser Surgeries

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Prevalence of Diabetic Conditions Among Adults
      • 3.2.2. Increasing Screen Time
    • 3.3. Market Challenges
      • 3.3.1. Lack of Trained Professionals
    • 3.4. Market Trends
      • 3.4.1. Technical Progress in Medical Industry
      • 3.4.2. Heavy Investments in Healthcare Research & Development
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Diabetic Retinopathy, by Type, Application, Retinopathy, Treatment and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Diabetic Retinopathy (Value)
      • 5.2.1. Global Diabetic Retinopathy by: Type (Value)
        • 5.2.1.1. Laser surgery
        • 5.2.1.2. Injection of corticosteroids
        • 5.2.1.3. Anti-VEGF drugs
        • 5.2.1.4. Vitrectomy
      • 5.2.2. Global Diabetic Retinopathy by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics and laboratories
        • 5.2.2.3. Others
      • 5.2.3. Global Diabetic Retinopathy by: Retinopathy (Value)
        • 5.2.3.1. Proliferative Diabetic Retinopathy
        • 5.2.3.2. Non-Proliferative Diabetic Retinopathy (NPDR)
      • 5.2.4. Global Diabetic Retinopathy by: Treatment (Value)
        • 5.2.4.1. Anti-VEGF Drug
        • 5.2.4.2. Vitrectomy
        • 5.2.4.3. Intraocular Steroid Implants
        • 5.2.4.4. Laser Surgeries
      • 5.2.5. Global Diabetic Retinopathy Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Diabetic Retinopathy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Alimera Science (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Allergan PLC (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Ampio Pharmaceuticals (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bayer AG (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Novartis AG (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Pfizer (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Regeneron Pharmaceuticals Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Bausch Health (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Diabetic Retinopathy Sale, by Type, Application, Retinopathy, Treatment and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Diabetic Retinopathy (Value)
      • 7.2.1. Global Diabetic Retinopathy by: Type (Value)
        • 7.2.1.1. Laser surgery
        • 7.2.1.2. Injection of corticosteroids
        • 7.2.1.3. Anti-VEGF drugs
        • 7.2.1.4. Vitrectomy
      • 7.2.2. Global Diabetic Retinopathy by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics and laboratories
        • 7.2.2.3. Others
      • 7.2.3. Global Diabetic Retinopathy by: Retinopathy (Value)
        • 7.2.3.1. Proliferative Diabetic Retinopathy
        • 7.2.3.2. Non-Proliferative Diabetic Retinopathy (NPDR)
      • 7.2.4. Global Diabetic Retinopathy by: Treatment (Value)
        • 7.2.4.1. Anti-VEGF Drug
        • 7.2.4.2. Vitrectomy
        • 7.2.4.3. Intraocular Steroid Implants
        • 7.2.4.4. Laser Surgeries
      • 7.2.5. Global Diabetic Retinopathy Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Diabetic Retinopathy: by Type(USD Million)
  • Table 2. Diabetic Retinopathy Laser surgery , by Region USD Million (2015-2020)
  • Table 3. Diabetic Retinopathy Injection of corticosteroids , by Region USD Million (2015-2020)
  • Table 4. Diabetic Retinopathy Anti-VEGF drugs , by Region USD Million (2015-2020)
  • Table 5. Diabetic Retinopathy Vitrectomy , by Region USD Million (2015-2020)
  • Table 6. Diabetic Retinopathy: by Application(USD Million)
  • Table 7. Diabetic Retinopathy Hospitals , by Region USD Million (2015-2020)
  • Table 8. Diabetic Retinopathy Clinics and laboratories , by Region USD Million (2015-2020)
  • Table 9. Diabetic Retinopathy Others , by Region USD Million (2015-2020)
  • Table 10. Diabetic Retinopathy: by Retinopathy(USD Million)
  • Table 11. Diabetic Retinopathy Proliferative Diabetic Retinopathy , by Region USD Million (2015-2020)
  • Table 12. Diabetic Retinopathy Non-Proliferative Diabetic Retinopathy (NPDR) , by Region USD Million (2015-2020)
  • Table 13. Diabetic Retinopathy: by Treatment(USD Million)
  • Table 14. Diabetic Retinopathy Anti-VEGF Drug , by Region USD Million (2015-2020)
  • Table 15. Diabetic Retinopathy Vitrectomy , by Region USD Million (2015-2020)
  • Table 16. Diabetic Retinopathy Intraocular Steroid Implants , by Region USD Million (2015-2020)
  • Table 17. Diabetic Retinopathy Laser Surgeries , by Region USD Million (2015-2020)
  • Table 18. South America Diabetic Retinopathy, by Country USD Million (2015-2020)
  • Table 19. South America Diabetic Retinopathy, by Type USD Million (2015-2020)
  • Table 20. South America Diabetic Retinopathy, by Application USD Million (2015-2020)
  • Table 21. South America Diabetic Retinopathy, by Retinopathy USD Million (2015-2020)
  • Table 22. South America Diabetic Retinopathy, by Treatment USD Million (2015-2020)
  • Table 23. Brazil Diabetic Retinopathy, by Type USD Million (2015-2020)
  • Table 24. Brazil Diabetic Retinopathy, by Application USD Million (2015-2020)
  • Table 25. Brazil Diabetic Retinopathy, by Retinopathy USD Million (2015-2020)
  • Table 26. Brazil Diabetic Retinopathy, by Treatment USD Million (2015-2020)
  • Table 27. Argentina Diabetic Retinopathy, by Type USD Million (2015-2020)
  • Table 28. Argentina Diabetic Retinopathy, by Application USD Million (2015-2020)
  • Table 29. Argentina Diabetic Retinopathy, by Retinopathy USD Million (2015-2020)
  • Table 30. Argentina Diabetic Retinopathy, by Treatment USD Million (2015-2020)
  • Table 31. Rest of South America Diabetic Retinopathy, by Type USD Million (2015-2020)
  • Table 32. Rest of South America Diabetic Retinopathy, by Application USD Million (2015-2020)
  • Table 33. Rest of South America Diabetic Retinopathy, by Retinopathy USD Million (2015-2020)
  • Table 34. Rest of South America Diabetic Retinopathy, by Treatment USD Million (2015-2020)
  • Table 35. Asia Pacific Diabetic Retinopathy, by Country USD Million (2015-2020)
  • Table 36. Asia Pacific Diabetic Retinopathy, by Type USD Million (2015-2020)
  • Table 37. Asia Pacific Diabetic Retinopathy, by Application USD Million (2015-2020)
  • Table 38. Asia Pacific Diabetic Retinopathy, by Retinopathy USD Million (2015-2020)
  • Table 39. Asia Pacific Diabetic Retinopathy, by Treatment USD Million (2015-2020)
  • Table 40. China Diabetic Retinopathy, by Type USD Million (2015-2020)
  • Table 41. China Diabetic Retinopathy, by Application USD Million (2015-2020)
  • Table 42. China Diabetic Retinopathy, by Retinopathy USD Million (2015-2020)
  • Table 43. China Diabetic Retinopathy, by Treatment USD Million (2015-2020)
  • Table 44. Japan Diabetic Retinopathy, by Type USD Million (2015-2020)
  • Table 45. Japan Diabetic Retinopathy, by Application USD Million (2015-2020)
  • Table 46. Japan Diabetic Retinopathy, by Retinopathy USD Million (2015-2020)
  • Table 47. Japan Diabetic Retinopathy, by Treatment USD Million (2015-2020)
  • Table 48. India Diabetic Retinopathy, by Type USD Million (2015-2020)
  • Table 49. India Diabetic Retinopathy, by Application USD Million (2015-2020)
  • Table 50. India Diabetic Retinopathy, by Retinopathy USD Million (2015-2020)
  • Table 51. India Diabetic Retinopathy, by Treatment USD Million (2015-2020)
  • Table 52. South Korea Diabetic Retinopathy, by Type USD Million (2015-2020)
  • Table 53. South Korea Diabetic Retinopathy, by Application USD Million (2015-2020)
  • Table 54. South Korea Diabetic Retinopathy, by Retinopathy USD Million (2015-2020)
  • Table 55. South Korea Diabetic Retinopathy, by Treatment USD Million (2015-2020)
  • Table 56. Taiwan Diabetic Retinopathy, by Type USD Million (2015-2020)
  • Table 57. Taiwan Diabetic Retinopathy, by Application USD Million (2015-2020)
  • Table 58. Taiwan Diabetic Retinopathy, by Retinopathy USD Million (2015-2020)
  • Table 59. Taiwan Diabetic Retinopathy, by Treatment USD Million (2015-2020)
  • Table 60. Australia Diabetic Retinopathy, by Type USD Million (2015-2020)
  • Table 61. Australia Diabetic Retinopathy, by Application USD Million (2015-2020)
  • Table 62. Australia Diabetic Retinopathy, by Retinopathy USD Million (2015-2020)
  • Table 63. Australia Diabetic Retinopathy, by Treatment USD Million (2015-2020)
  • Table 64. Rest of Asia-Pacific Diabetic Retinopathy, by Type USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Diabetic Retinopathy, by Application USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Diabetic Retinopathy, by Retinopathy USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Diabetic Retinopathy, by Treatment USD Million (2015-2020)
  • Table 68. Europe Diabetic Retinopathy, by Country USD Million (2015-2020)
  • Table 69. Europe Diabetic Retinopathy, by Type USD Million (2015-2020)
  • Table 70. Europe Diabetic Retinopathy, by Application USD Million (2015-2020)
  • Table 71. Europe Diabetic Retinopathy, by Retinopathy USD Million (2015-2020)
  • Table 72. Europe Diabetic Retinopathy, by Treatment USD Million (2015-2020)
  • Table 73. Germany Diabetic Retinopathy, by Type USD Million (2015-2020)
  • Table 74. Germany Diabetic Retinopathy, by Application USD Million (2015-2020)
  • Table 75. Germany Diabetic Retinopathy, by Retinopathy USD Million (2015-2020)
  • Table 76. Germany Diabetic Retinopathy, by Treatment USD Million (2015-2020)
  • Table 77. France Diabetic Retinopathy, by Type USD Million (2015-2020)
  • Table 78. France Diabetic Retinopathy, by Application USD Million (2015-2020)
  • Table 79. France Diabetic Retinopathy, by Retinopathy USD Million (2015-2020)
  • Table 80. France Diabetic Retinopathy, by Treatment USD Million (2015-2020)
  • Table 81. Italy Diabetic Retinopathy, by Type USD Million (2015-2020)
  • Table 82. Italy Diabetic Retinopathy, by Application USD Million (2015-2020)
  • Table 83. Italy Diabetic Retinopathy, by Retinopathy USD Million (2015-2020)
  • Table 84. Italy Diabetic Retinopathy, by Treatment USD Million (2015-2020)
  • Table 85. United Kingdom Diabetic Retinopathy, by Type USD Million (2015-2020)
  • Table 86. United Kingdom Diabetic Retinopathy, by Application USD Million (2015-2020)
  • Table 87. United Kingdom Diabetic Retinopathy, by Retinopathy USD Million (2015-2020)
  • Table 88. United Kingdom Diabetic Retinopathy, by Treatment USD Million (2015-2020)
  • Table 89. Netherlands Diabetic Retinopathy, by Type USD Million (2015-2020)
  • Table 90. Netherlands Diabetic Retinopathy, by Application USD Million (2015-2020)
  • Table 91. Netherlands Diabetic Retinopathy, by Retinopathy USD Million (2015-2020)
  • Table 92. Netherlands Diabetic Retinopathy, by Treatment USD Million (2015-2020)
  • Table 93. Rest of Europe Diabetic Retinopathy, by Type USD Million (2015-2020)
  • Table 94. Rest of Europe Diabetic Retinopathy, by Application USD Million (2015-2020)
  • Table 95. Rest of Europe Diabetic Retinopathy, by Retinopathy USD Million (2015-2020)
  • Table 96. Rest of Europe Diabetic Retinopathy, by Treatment USD Million (2015-2020)
  • Table 97. MEA Diabetic Retinopathy, by Country USD Million (2015-2020)
  • Table 98. MEA Diabetic Retinopathy, by Type USD Million (2015-2020)
  • Table 99. MEA Diabetic Retinopathy, by Application USD Million (2015-2020)
  • Table 100. MEA Diabetic Retinopathy, by Retinopathy USD Million (2015-2020)
  • Table 101. MEA Diabetic Retinopathy, by Treatment USD Million (2015-2020)
  • Table 102. Middle East Diabetic Retinopathy, by Type USD Million (2015-2020)
  • Table 103. Middle East Diabetic Retinopathy, by Application USD Million (2015-2020)
  • Table 104. Middle East Diabetic Retinopathy, by Retinopathy USD Million (2015-2020)
  • Table 105. Middle East Diabetic Retinopathy, by Treatment USD Million (2015-2020)
  • Table 106. Africa Diabetic Retinopathy, by Type USD Million (2015-2020)
  • Table 107. Africa Diabetic Retinopathy, by Application USD Million (2015-2020)
  • Table 108. Africa Diabetic Retinopathy, by Retinopathy USD Million (2015-2020)
  • Table 109. Africa Diabetic Retinopathy, by Treatment USD Million (2015-2020)
  • Table 110. North America Diabetic Retinopathy, by Country USD Million (2015-2020)
  • Table 111. North America Diabetic Retinopathy, by Type USD Million (2015-2020)
  • Table 112. North America Diabetic Retinopathy, by Application USD Million (2015-2020)
  • Table 113. North America Diabetic Retinopathy, by Retinopathy USD Million (2015-2020)
  • Table 114. North America Diabetic Retinopathy, by Treatment USD Million (2015-2020)
  • Table 115. United States Diabetic Retinopathy, by Type USD Million (2015-2020)
  • Table 116. United States Diabetic Retinopathy, by Application USD Million (2015-2020)
  • Table 117. United States Diabetic Retinopathy, by Retinopathy USD Million (2015-2020)
  • Table 118. United States Diabetic Retinopathy, by Treatment USD Million (2015-2020)
  • Table 119. Canada Diabetic Retinopathy, by Type USD Million (2015-2020)
  • Table 120. Canada Diabetic Retinopathy, by Application USD Million (2015-2020)
  • Table 121. Canada Diabetic Retinopathy, by Retinopathy USD Million (2015-2020)
  • Table 122. Canada Diabetic Retinopathy, by Treatment USD Million (2015-2020)
  • Table 123. Mexico Diabetic Retinopathy, by Type USD Million (2015-2020)
  • Table 124. Mexico Diabetic Retinopathy, by Application USD Million (2015-2020)
  • Table 125. Mexico Diabetic Retinopathy, by Retinopathy USD Million (2015-2020)
  • Table 126. Mexico Diabetic Retinopathy, by Treatment USD Million (2015-2020)
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Diabetic Retinopathy: by Type(USD Million)
  • Table 138. Diabetic Retinopathy Laser surgery , by Region USD Million (2021-2026)
  • Table 139. Diabetic Retinopathy Injection of corticosteroids , by Region USD Million (2021-2026)
  • Table 140. Diabetic Retinopathy Anti-VEGF drugs , by Region USD Million (2021-2026)
  • Table 141. Diabetic Retinopathy Vitrectomy , by Region USD Million (2021-2026)
  • Table 142. Diabetic Retinopathy: by Application(USD Million)
  • Table 143. Diabetic Retinopathy Hospitals , by Region USD Million (2021-2026)
  • Table 144. Diabetic Retinopathy Clinics and laboratories , by Region USD Million (2021-2026)
  • Table 145. Diabetic Retinopathy Others , by Region USD Million (2021-2026)
  • Table 146. Diabetic Retinopathy: by Retinopathy(USD Million)
  • Table 147. Diabetic Retinopathy Proliferative Diabetic Retinopathy , by Region USD Million (2021-2026)
  • Table 148. Diabetic Retinopathy Non-Proliferative Diabetic Retinopathy (NPDR) , by Region USD Million (2021-2026)
  • Table 149. Diabetic Retinopathy: by Treatment(USD Million)
  • Table 150. Diabetic Retinopathy Anti-VEGF Drug , by Region USD Million (2021-2026)
  • Table 151. Diabetic Retinopathy Vitrectomy , by Region USD Million (2021-2026)
  • Table 152. Diabetic Retinopathy Intraocular Steroid Implants , by Region USD Million (2021-2026)
  • Table 153. Diabetic Retinopathy Laser Surgeries , by Region USD Million (2021-2026)
  • Table 154. South America Diabetic Retinopathy, by Country USD Million (2021-2026)
  • Table 155. South America Diabetic Retinopathy, by Type USD Million (2021-2026)
  • Table 156. South America Diabetic Retinopathy, by Application USD Million (2021-2026)
  • Table 157. South America Diabetic Retinopathy, by Retinopathy USD Million (2021-2026)
  • Table 158. South America Diabetic Retinopathy, by Treatment USD Million (2021-2026)
  • Table 159. Brazil Diabetic Retinopathy, by Type USD Million (2021-2026)
  • Table 160. Brazil Diabetic Retinopathy, by Application USD Million (2021-2026)
  • Table 161. Brazil Diabetic Retinopathy, by Retinopathy USD Million (2021-2026)
  • Table 162. Brazil Diabetic Retinopathy, by Treatment USD Million (2021-2026)
  • Table 163. Argentina Diabetic Retinopathy, by Type USD Million (2021-2026)
  • Table 164. Argentina Diabetic Retinopathy, by Application USD Million (2021-2026)
  • Table 165. Argentina Diabetic Retinopathy, by Retinopathy USD Million (2021-2026)
  • Table 166. Argentina Diabetic Retinopathy, by Treatment USD Million (2021-2026)
  • Table 167. Rest of South America Diabetic Retinopathy, by Type USD Million (2021-2026)
  • Table 168. Rest of South America Diabetic Retinopathy, by Application USD Million (2021-2026)
  • Table 169. Rest of South America Diabetic Retinopathy, by Retinopathy USD Million (2021-2026)
  • Table 170. Rest of South America Diabetic Retinopathy, by Treatment USD Million (2021-2026)
  • Table 171. Asia Pacific Diabetic Retinopathy, by Country USD Million (2021-2026)
  • Table 172. Asia Pacific Diabetic Retinopathy, by Type USD Million (2021-2026)
  • Table 173. Asia Pacific Diabetic Retinopathy, by Application USD Million (2021-2026)
  • Table 174. Asia Pacific Diabetic Retinopathy, by Retinopathy USD Million (2021-2026)
  • Table 175. Asia Pacific Diabetic Retinopathy, by Treatment USD Million (2021-2026)
  • Table 176. China Diabetic Retinopathy, by Type USD Million (2021-2026)
  • Table 177. China Diabetic Retinopathy, by Application USD Million (2021-2026)
  • Table 178. China Diabetic Retinopathy, by Retinopathy USD Million (2021-2026)
  • Table 179. China Diabetic Retinopathy, by Treatment USD Million (2021-2026)
  • Table 180. Japan Diabetic Retinopathy, by Type USD Million (2021-2026)
  • Table 181. Japan Diabetic Retinopathy, by Application USD Million (2021-2026)
  • Table 182. Japan Diabetic Retinopathy, by Retinopathy USD Million (2021-2026)
  • Table 183. Japan Diabetic Retinopathy, by Treatment USD Million (2021-2026)
  • Table 184. India Diabetic Retinopathy, by Type USD Million (2021-2026)
  • Table 185. India Diabetic Retinopathy, by Application USD Million (2021-2026)
  • Table 186. India Diabetic Retinopathy, by Retinopathy USD Million (2021-2026)
  • Table 187. India Diabetic Retinopathy, by Treatment USD Million (2021-2026)
  • Table 188. South Korea Diabetic Retinopathy, by Type USD Million (2021-2026)
  • Table 189. South Korea Diabetic Retinopathy, by Application USD Million (2021-2026)
  • Table 190. South Korea Diabetic Retinopathy, by Retinopathy USD Million (2021-2026)
  • Table 191. South Korea Diabetic Retinopathy, by Treatment USD Million (2021-2026)
  • Table 192. Taiwan Diabetic Retinopathy, by Type USD Million (2021-2026)
  • Table 193. Taiwan Diabetic Retinopathy, by Application USD Million (2021-2026)
  • Table 194. Taiwan Diabetic Retinopathy, by Retinopathy USD Million (2021-2026)
  • Table 195. Taiwan Diabetic Retinopathy, by Treatment USD Million (2021-2026)
  • Table 196. Australia Diabetic Retinopathy, by Type USD Million (2021-2026)
  • Table 197. Australia Diabetic Retinopathy, by Application USD Million (2021-2026)
  • Table 198. Australia Diabetic Retinopathy, by Retinopathy USD Million (2021-2026)
  • Table 199. Australia Diabetic Retinopathy, by Treatment USD Million (2021-2026)
  • Table 200. Rest of Asia-Pacific Diabetic Retinopathy, by Type USD Million (2021-2026)
  • Table 201. Rest of Asia-Pacific Diabetic Retinopathy, by Application USD Million (2021-2026)
  • Table 202. Rest of Asia-Pacific Diabetic Retinopathy, by Retinopathy USD Million (2021-2026)
  • Table 203. Rest of Asia-Pacific Diabetic Retinopathy, by Treatment USD Million (2021-2026)
  • Table 204. Europe Diabetic Retinopathy, by Country USD Million (2021-2026)
  • Table 205. Europe Diabetic Retinopathy, by Type USD Million (2021-2026)
  • Table 206. Europe Diabetic Retinopathy, by Application USD Million (2021-2026)
  • Table 207. Europe Diabetic Retinopathy, by Retinopathy USD Million (2021-2026)
  • Table 208. Europe Diabetic Retinopathy, by Treatment USD Million (2021-2026)
  • Table 209. Germany Diabetic Retinopathy, by Type USD Million (2021-2026)
  • Table 210. Germany Diabetic Retinopathy, by Application USD Million (2021-2026)
  • Table 211. Germany Diabetic Retinopathy, by Retinopathy USD Million (2021-2026)
  • Table 212. Germany Diabetic Retinopathy, by Treatment USD Million (2021-2026)
  • Table 213. France Diabetic Retinopathy, by Type USD Million (2021-2026)
  • Table 214. France Diabetic Retinopathy, by Application USD Million (2021-2026)
  • Table 215. France Diabetic Retinopathy, by Retinopathy USD Million (2021-2026)
  • Table 216. France Diabetic Retinopathy, by Treatment USD Million (2021-2026)
  • Table 217. Italy Diabetic Retinopathy, by Type USD Million (2021-2026)
  • Table 218. Italy Diabetic Retinopathy, by Application USD Million (2021-2026)
  • Table 219. Italy Diabetic Retinopathy, by Retinopathy USD Million (2021-2026)
  • Table 220. Italy Diabetic Retinopathy, by Treatment USD Million (2021-2026)
  • Table 221. United Kingdom Diabetic Retinopathy, by Type USD Million (2021-2026)
  • Table 222. United Kingdom Diabetic Retinopathy, by Application USD Million (2021-2026)
  • Table 223. United Kingdom Diabetic Retinopathy, by Retinopathy USD Million (2021-2026)
  • Table 224. United Kingdom Diabetic Retinopathy, by Treatment USD Million (2021-2026)
  • Table 225. Netherlands Diabetic Retinopathy, by Type USD Million (2021-2026)
  • Table 226. Netherlands Diabetic Retinopathy, by Application USD Million (2021-2026)
  • Table 227. Netherlands Diabetic Retinopathy, by Retinopathy USD Million (2021-2026)
  • Table 228. Netherlands Diabetic Retinopathy, by Treatment USD Million (2021-2026)
  • Table 229. Rest of Europe Diabetic Retinopathy, by Type USD Million (2021-2026)
  • Table 230. Rest of Europe Diabetic Retinopathy, by Application USD Million (2021-2026)
  • Table 231. Rest of Europe Diabetic Retinopathy, by Retinopathy USD Million (2021-2026)
  • Table 232. Rest of Europe Diabetic Retinopathy, by Treatment USD Million (2021-2026)
  • Table 233. MEA Diabetic Retinopathy, by Country USD Million (2021-2026)
  • Table 234. MEA Diabetic Retinopathy, by Type USD Million (2021-2026)
  • Table 235. MEA Diabetic Retinopathy, by Application USD Million (2021-2026)
  • Table 236. MEA Diabetic Retinopathy, by Retinopathy USD Million (2021-2026)
  • Table 237. MEA Diabetic Retinopathy, by Treatment USD Million (2021-2026)
  • Table 238. Middle East Diabetic Retinopathy, by Type USD Million (2021-2026)
  • Table 239. Middle East Diabetic Retinopathy, by Application USD Million (2021-2026)
  • Table 240. Middle East Diabetic Retinopathy, by Retinopathy USD Million (2021-2026)
  • Table 241. Middle East Diabetic Retinopathy, by Treatment USD Million (2021-2026)
  • Table 242. Africa Diabetic Retinopathy, by Type USD Million (2021-2026)
  • Table 243. Africa Diabetic Retinopathy, by Application USD Million (2021-2026)
  • Table 244. Africa Diabetic Retinopathy, by Retinopathy USD Million (2021-2026)
  • Table 245. Africa Diabetic Retinopathy, by Treatment USD Million (2021-2026)
  • Table 246. North America Diabetic Retinopathy, by Country USD Million (2021-2026)
  • Table 247. North America Diabetic Retinopathy, by Type USD Million (2021-2026)
  • Table 248. North America Diabetic Retinopathy, by Application USD Million (2021-2026)
  • Table 249. North America Diabetic Retinopathy, by Retinopathy USD Million (2021-2026)
  • Table 250. North America Diabetic Retinopathy, by Treatment USD Million (2021-2026)
  • Table 251. United States Diabetic Retinopathy, by Type USD Million (2021-2026)
  • Table 252. United States Diabetic Retinopathy, by Application USD Million (2021-2026)
  • Table 253. United States Diabetic Retinopathy, by Retinopathy USD Million (2021-2026)
  • Table 254. United States Diabetic Retinopathy, by Treatment USD Million (2021-2026)
  • Table 255. Canada Diabetic Retinopathy, by Type USD Million (2021-2026)
  • Table 256. Canada Diabetic Retinopathy, by Application USD Million (2021-2026)
  • Table 257. Canada Diabetic Retinopathy, by Retinopathy USD Million (2021-2026)
  • Table 258. Canada Diabetic Retinopathy, by Treatment USD Million (2021-2026)
  • Table 259. Mexico Diabetic Retinopathy, by Type USD Million (2021-2026)
  • Table 260. Mexico Diabetic Retinopathy, by Application USD Million (2021-2026)
  • Table 261. Mexico Diabetic Retinopathy, by Retinopathy USD Million (2021-2026)
  • Table 262. Mexico Diabetic Retinopathy, by Treatment USD Million (2021-2026)
  • Table 263. Research Programs/Design for This Report
  • Table 264. Key Data Information from Secondary Sources
  • Table 265. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Diabetic Retinopathy: by Type USD Million (2015-2020)
  • Figure 5. Global Diabetic Retinopathy: by Application USD Million (2015-2020)
  • Figure 6. Global Diabetic Retinopathy: by Retinopathy USD Million (2015-2020)
  • Figure 7. Global Diabetic Retinopathy: by Treatment USD Million (2015-2020)
  • Figure 8. South America Diabetic Retinopathy Share (%), by Country
  • Figure 9. Asia Pacific Diabetic Retinopathy Share (%), by Country
  • Figure 10. Europe Diabetic Retinopathy Share (%), by Country
  • Figure 11. MEA Diabetic Retinopathy Share (%), by Country
  • Figure 12. North America Diabetic Retinopathy Share (%), by Country
  • Figure 13. Global Diabetic Retinopathy share by Players 2020 (%)
  • Figure 14. Global Diabetic Retinopathy share by Players (Top 3) 2020(%)
  • Figure 15. Global Diabetic Retinopathy share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 18. Abbott Laboratories (United States) Revenue: by Geography 2020
  • Figure 19. Alimera Science (United States) Revenue, Net Income and Gross profit
  • Figure 20. Alimera Science (United States) Revenue: by Geography 2020
  • Figure 21. Allergan PLC (India) Revenue, Net Income and Gross profit
  • Figure 22. Allergan PLC (India) Revenue: by Geography 2020
  • Figure 23. Ampio Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 24. Ampio Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 25. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 26. Bayer AG (Germany) Revenue: by Geography 2020
  • Figure 27. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 28. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2020
  • Figure 29. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 31. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 32. Pfizer (United States) Revenue: by Geography 2020
  • Figure 33. Regeneron Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Regeneron Pharmaceuticals Inc. (United States) Revenue: by Geography 2020
  • Figure 35. Bausch Health (United States) Revenue, Net Income and Gross profit
  • Figure 36. Bausch Health (United States) Revenue: by Geography 2020
  • Figure 37. Global Diabetic Retinopathy: by Type USD Million (2021-2026)
  • Figure 38. Global Diabetic Retinopathy: by Application USD Million (2021-2026)
  • Figure 39. Global Diabetic Retinopathy: by Retinopathy USD Million (2021-2026)
  • Figure 40. Global Diabetic Retinopathy: by Treatment USD Million (2021-2026)
  • Figure 41. South America Diabetic Retinopathy Share (%), by Country
  • Figure 42. Asia Pacific Diabetic Retinopathy Share (%), by Country
  • Figure 43. Europe Diabetic Retinopathy Share (%), by Country
  • Figure 44. MEA Diabetic Retinopathy Share (%), by Country
  • Figure 45. North America Diabetic Retinopathy Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Abbott Laboratories (United States)
  • Alimera Science (United States)
  • Allergan PLC (India)
  • Ampio Pharmaceuticals (United States)
  • Bayer AG (Germany)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Novartis AG (Switzerland)
  • Pfizer (United States)
  • Regeneron Pharmaceuticals Inc. (United States)
  • Bausch Health (United States)
Additional players considered in the study are as follows:
NovaGo Theraputics (Switzerland) , Eyenuk (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation